Registration number:
Cellshield Limited
Unaudited Financial Statements
31 December 2025
Cellshield Limited
Statement of Financial Position
31 December 2025
|
Note |
2025 |
2024 |
|
|
Current assets |
|||
|
Debtors |
|
|
|
|
Capital and reserves |
|||
|
Called up share capital |
|
|
|
|
Shareholders' funds |
|
|
For the financial year ending 31 December 2025 the Company was entitled to exemption from audit under section 480 of the Companies Act 2006 relating to dormant companies.
Directors' responsibilities:
|
• |
|
|
• |
The Directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts. |
These financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and FRS 102 ‘The Financial Reporting Standard Applicable in the UK and Republic of Ireland’.
Approved and authorised by the
|
......................................... |
Company Registration Number: 1818559
Cellshield Limited
Notes to the Unaudited Financial Statements
31 December 2025
|
General information |
The Company is a private company limited by share capital, incorporated in England.
The address of its registered office is:
These financial statements were authorised for issue by the
|
Accounting policies |
Summary of significant accounting policies and key accounting estimates
The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.
Statement of compliance
These financial statements have been prepared in accordance with applicable United Kingdom accounting standards, including Financial Reporting Standard 102 – 'The Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland' ('FRS 102'), and with the Companies Act 2006.
Basis of preparation
The financial statements have been prepared under the historical cost convention.
As noted in the Directors report, the directors consider that the going concern basis of accounting is appropriate. In making this decision the directors have considered the impact of the Covid 19 pandemic on the company.
The financial statements are prepared in sterling which is the functional currency of the company.
Departure from requirements of FRS 102
The company is a wholly owned subsidiary of William Hare Group Limited, the consolidated accounts of which are publicly available. Accordingly, the company has taken advantage of the exemption in FRS 102 from disclosing transactions with members or investees of the William Hare Group Limited group. |
Share capital
Ordinary shares are classified as equity. Equity instruments are measured at the fair value of the cash or other resources received or receivable, net of the direct costs of issuing the equity instruments. If payment is deferred and the time value of money is material, the initial measurement is on a present value basis.
Cellshield Limited
Notes to the Unaudited Financial Statements
31 December 2025
|
Debtors |
|
Current |
Note |
2025 |
2024 |
|
Amounts owed by related parties |
|
|
|
|
|
|
|
Share capital |
Allotted, called up and fully paid shares
|
2025 |
2024 |
|||
|
No. |
£ |
No. |
£ |
|
|
|
|
200 |
|
200 |
|
Related party transactions |
No transactions with related parties were undertaken such as are required to be disclosed under FRS 102.
|
Parent and ultimate parent undertaking |
The company regards Orange UK Holdings Limited, registered in England, as its ultimate holding company.
The company is considered to be under the control of the majority of the directors of the ultimate holding company.
|
Staff numbers |
The average number of persons employed by the company (including directors) during the year, was